EBioMedicine. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development

[tetano]

EBioMedicine. 2020 Apr 16;55:102768. doi: 10.1016/j.ebiom.2020.102768. [Epub ahead of print]
Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.


de Alwis R¹, Chen S², Gan ES², Ooi EE³.

Author information




Abstract

The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.
Copyright ? 2020 The Author(s). Published by Elsevier B.V. All rights reserved.



KEYWORDS:

COVID-19; Coronavirus; Polyclonal hyperimmune globulin; SARS-CoV-2; Vaccines


PMID:32344202DOI:10.1016/j.ebiom.2020.102768
Free full text